...
首页> 外文期刊>British Journal of Cancer >Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification
【24h】

Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification

机译:分段染色体异常对12月龄以上不能切除的局限性周围神经母细胞瘤而未 MYCN 扩增的儿童生存的影响

获取原文

摘要

Background: The prognostic impact of segmental chromosome alterations (SCAs) in children older than 1 year, diagnosed with localised unresectable neuroblastoma (NB) without MYCN amplification enrolled in the European Unresectable Neuroblastoma (EUNB) protocol is still to be clarified, while, for other group of patients, the presence of SCAs is associated with poor prognosis. Methods: To understand the role of SCAs we performed multilocus/pangenomic analysis of 98 tumour samples from patients enrolled in the EUNB protocol. Results: Age at diagnosis was categorised into two groups using 18 months as the age cutoff. Significant difference in the presence of SCAs was seen in tumours of patients between 12 and 18 months and over 18 months of age at diagnosis, respectively ( P =0.04). A significant correlation ( P =0.03) was observed between number of SCAs per tumour and age. Event-free (EFS) and overall survival (OS) were calculated in both age groups, according to both the presence and number of SCAs. In older patients, a poorer survival was associated with the presence of SCAs (EFS=46% vs 75%, P =0.023; OS=66.8% vs 100%, P =0.003). Moreover, OS of older patients inversely correlated with number of SCAs ( P =0.002). Finally, SCAs provided additional prognostic information beyond histoprognosis, as their presence was associated with poorer OS in patients over 18 months with unfavourable International Neuroblastoma Pathology Classification (INPC) histopathology ( P =0.018). Conclusions: The presence of SCAs is a negative prognostic marker that impairs outcome of patients over the age of 18 months with localised unresectable NB without MYCN amplification, especially when more than one SCA is present. Moreover, in older patients with unfavourable INPC tumour histoprognosis, the presence of SCAs significantly affects OS.
机译:背景:欧洲不可切除神经母细胞瘤(EUNB)方案中未诊断为MYCN扩增的局限性不可切除神经母细胞瘤(NB)被诊断为1岁以上儿童的节段染色体改变(SCA)对预后的影响尚待阐明,而对于其他SCA患者的存在与预后不良有关。方法:为了了解SCA的作用,我们对来自EUNB方案的患者的98个肿瘤样本进行了多基因座/基因组分析。结果:以18个月为截止年龄,将诊断时的年龄分为两组。在诊断时分别在12到18个月之间以及18个月以上的患者的肿瘤中发现SCA的存在显着差异(P = 0.04)。每个肿瘤的SCA数量与年龄之间存在显着相关性(P = 0.03)。根据SCA的存在和数量,计算了两个年龄段的无事件(EFS)和总生存期(OS)。在老年患者中,较差的生存与SCA的存在有关(EFS = 46%vs 75%,P = 0.023; OS = 66.8%vs 100%,P = 0.003)。此外,老年患者的OS与SCA的数量成反比(P = 0.002)。最后,SCAs提供了除组织学预后之外的其他预后信息,因为在国际神经母细胞瘤病理分类(INPC)病理学不佳的情况下,存在18个月以上的患者OS较差(P = 0.018)。结论:SCAs的存在是阴性的预后指标,它会损害18个月以上患有局灶性不可切除NB而无MYCN扩增的患者的预后,尤其是当存在多个SCA时。此外,在INPC肿瘤组织学预后不良的老年患者中,SCA的存在会显着影响OS。

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号